Hologic Stitches Medical Aesthetics Into Women's Health
Executive Summary
Hologic is acquiring Cynosure for $1.65bn, saying medical aesthetics will complement its existing OB/GYN and women’s health businesses. It is the latest in a series of recent moves intended to accelerate Hologic’s growth.
You may also be interested in...
'We Survived MDSAP': Cynosure Aces Single-Audit Program Twice; Tells How Your Firm Can, Too
Connie Hoy, executive VP of clinical development and regulatory affairs for the Westford, Mass.-based device-maker, explains how the firm handled audits at two separate facilities under the Medical Device Single Audit Program. Hoy details how her MDSAP experiences unfolded, from the time she was first notified – "I thought, 'I'm either going back to bed or I better turn my fierce on,' so I turned my fierce on" – to the very end of each audit, when the company was handed a few auditor findings that were easily fixed. "There’s not one company that cannot pass the MDSAP audit," Hoy insists. Check out her valuable tips and advice – and colorful anecdotes – in this feature article.
M&A Analysis: M&A Rises In 2017 As Market Set To Bounce Back In 2018
2017 proved to be a busy year for medtech M&A activity, with the number of deals rising from 174 in 2016, to 206 in 2017. The year also brought a number of notable acquisitions, including Becton Dickinson's blockbuster $24bn purchase of CR Bard and Dutch health-care giant Philips undertaking an ambitious acquisition spree. Medtech Insight takes a look at the highlights of 2017 and what's in store for 2018.
Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.